P. Foro

1.4k total citations
65 papers, 1.0k citations indexed

About

P. Foro is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, P. Foro has authored 65 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Pulmonary and Respiratory Medicine, 23 papers in Oncology and 19 papers in Surgery. Recurrent topics in P. Foro's work include Breast Cancer Treatment Studies (14 papers), Prostate Cancer Treatment and Research (11 papers) and Glioma Diagnosis and Treatment (9 papers). P. Foro is often cited by papers focused on Breast Cancer Treatment Studies (14 papers), Prostate Cancer Treatment and Research (11 papers) and Glioma Diagnosis and Treatment (9 papers). P. Foro collaborates with scholars based in Spain, Canada and China. P. Foro's co-authors include M. Algara, I. Membrive, Núria Rodríguez, J. Lozano, A. Reig, X. Sanz, E. Fernández-Velilla, Joan Carles, J. Quera and Edward Chow and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

P. Foro

64 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
P. Foro Spain 15 400 373 340 222 206 65 1.0k
Kumiko Karasawa Japan 20 330 0.8× 321 0.9× 508 1.5× 191 0.9× 79 0.4× 127 1.2k
Jeongshim Lee South Korea 16 264 0.7× 230 0.6× 195 0.6× 157 0.7× 124 0.6× 54 715
Quynh‐Nhu Nguyen United States 16 297 0.7× 451 1.2× 409 1.2× 76 0.3× 79 0.4× 55 1.0k
Tabassum Wadasadawala India 15 143 0.4× 265 0.7× 163 0.5× 261 1.2× 102 0.5× 74 684
Jennifer A. Dorth United States 15 248 0.6× 371 1.0× 272 0.8× 76 0.3× 115 0.6× 60 837
É. Luporsi France 19 292 0.7× 545 1.5× 232 0.7× 255 1.1× 116 0.6× 66 1.0k
Giovanni Silvano Italy 14 617 1.5× 656 1.8× 351 1.0× 79 0.4× 125 0.6× 50 1.1k
Kilian Salerno United States 16 345 0.9× 437 1.2× 458 1.3× 461 2.1× 251 1.2× 46 1.1k
Corinne Doll Canada 20 388 1.0× 401 1.1× 207 0.6× 161 0.7× 71 0.3× 70 1.1k
Rami A. El Shafie Germany 18 274 0.7× 521 1.4× 475 1.4× 115 0.5× 39 0.2× 66 957

Countries citing papers authored by P. Foro

Since Specialization
Citations

This map shows the geographic impact of P. Foro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Foro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Foro more than expected).

Fields of papers citing papers by P. Foro

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Foro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Foro. The network helps show where P. Foro may publish in the future.

Co-authorship network of co-authors of P. Foro

This figure shows the co-authorship network connecting the top 25 collaborators of P. Foro. A scholar is included among the top collaborators of P. Foro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Foro. P. Foro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
2.
Sepúlveda-Sánchez, Juan Manuel, Maria Martinez‐García, P. Foro, et al.. (2024). 454P Tetrahydrocannabinol (THC) / cannabidiol (CBD) oral solution in combination with temozolomide (TMZ) and radiotherapy (RT) in patients with newly diagnosed glioblastoma: Phase Ib GEINO-1601 trial. Annals of Oncology. 35. S411–S411. 1 indexed citations
3.
Foro, P., et al.. (2023). A Phase II Trial of Intraoperative Radiotherapy after Surgical Resection of Brain Metastases: Feasibility and Efficacy NCT04847284. International Journal of Radiation Oncology*Biology*Physics. 117(2). e104–e104. 1 indexed citations
4.
Martinez‐García, Maria, Guillermo Velasco, Estela Pineda, et al.. (2022). Safety and Efficacy of Crizotinib in Combination with Temozolomide and Radiotherapy in Patients with Newly Diagnosed Glioblastoma: Phase Ib GEINO 1402 Trial. Cancers. 14(10). 2393–2393. 16 indexed citations
5.
Membrive, I., et al.. (2021). Validation of 3D printing materials for high dose-rate brachytherapy using ionisation chamber and custom phantom. Physics in Medicine and Biology. 66(18). 18NT04–18NT04. 4 indexed citations
7.
Membrive, I., P. Foro, Núria Rodríguez, et al.. (2021). High-dose-rate plesiotherapy with customized molds in non-melanoma skin cancer: efficacy and safety at 10 years—single institution experience. Clinical & Translational Oncology. 24(3). 578–585. 3 indexed citations
8.
Huang, Yuhua, Núria Rodríguez, Xavier Durán, et al.. (2021). Quantitative assessments of late radiation-induced skin and soft tissue toxicity and correlation with RTOG scales and biological equivalent dose in breast cancer. Clinical & Translational Oncology. 24(5). 836–845. 6 indexed citations
9.
Guillén-Solà, Anna, et al.. (2020). Is EAT-10 Useful to Assess Swallowing during the Chemo-Radiotherapy Phase in Patients with Head and Neck Cancer? A Pilot Study. Annals of Otology Rhinology & Laryngology. 130(7). 689–698. 9 indexed citations
11.
Carles, Joan, Enrique Gallardo, Montserrat Domènech, et al.. (2018). Phase 2 Randomized Study of Radiation Therapy and 3-Year Androgen Deprivation With or Without Concurrent Weekly Docetaxel in High-Risk Localized Prostate Cancer Patients. International Journal of Radiation Oncology*Biology*Physics. 103(2). 344–352. 5 indexed citations
13.
Henríquez‐Hernández, Luis Alberto, P. Foro, María Jesús Álvarez-Cubero, et al.. (2015). Intraethnic variation in steroid-5-alpha-reductase polymorphisms in prostate cancer patients: a potential factor implicated in 5-alpha-reductase inhibitor treatment. Journal of Genetics. 94(2). 335–341. 2 indexed citations
14.
Rodríguez, Núria, X. Sanz, P. Foro, et al.. (2013). Five-Year Outcomes, Cosmesis, and Toxicity With 3-Dimensional Conformal External Beam Radiation Therapy to Deliver Accelerated Partial Breast Irradiation. International Journal of Radiation Oncology*Biology*Physics. 87(5). 1051–1057. 121 indexed citations
15.
Membrive, I., P. Foro, X. Sanz, et al.. (2010). Testicular Dose and Hormonal Changes after Radiotherapy in Rectal Cancer. International Journal of Radiation Oncology*Biology*Physics. 78(3). S315–S315. 1 indexed citations
16.
Rodríguez, Núria, M. Algara, P. Foro, et al.. (2008). Predictors of Acute Esophagitis in Lung Cancer Patients Treated With Concurrent Three-Dimensional Conformal Radiotherapy and Chemotherapy. International Journal of Radiation Oncology*Biology*Physics. 73(3). 810–817. 45 indexed citations
17.
Algara, M., et al.. (2008). Use of radiation treatment units in breast cancer. Changes in the last 15 years. Clinical & Translational Oncology. 10(1). 47–51. 2 indexed citations
18.
Guerra, José Luis López, P. Foro, & M. Algara. (2008). Breast metastases from a floor of the mouth carcinoma. Clinical & Translational Oncology. 10(8). 522–524. 3 indexed citations
19.
Algara, M., P. Foro, Jacint Jordana, et al.. (2007). Risk factors of local relapse in breast cancer: the importance of age. Clinical & Translational Oncology. 9(2). 110–116. 13 indexed citations
20.
Verdú-Rotellar, José María, et al.. (2002). Atención a los efectos secundarios de la radioterapia. 12(7). 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026